142nd APHA Annual Meeting and Exposition

Annual Meeting Recordings are now available for purchase

312163
Prevalence of substance use problems in HIV-positive patients attending comprehensive care clinics in NYC

142nd APHA Annual Meeting and Exposition (November 15 - November 19, 2014): http://www.apha.org/events-and-meetings/annual
Wednesday, November 19, 2014

Jeffrey T. Parsons, PhD , Department of Psychology and the Center for HIV/AIDS Educational Studies and Training (CHEST), Hunter College and the Graduate Center of the City University of New York (CUNY), New York, NY
H. Jonathon Rendina, PhD, MPH , Center for HIV/AIDS Educational Studies and Training (CHEST), Department of Psychology, Hunter College of the City University of New York (CUNY), New York, NY
Ana Ventuneac, PhD , Center for HIV/AIDS Educational Studies and Training (CHEST), Hunter College of the City University of New York (CUNY), New York, NY
Hannah Wolfe, PhD , Spencer Cox Center for Health, St. Luke's-Roosevelt Hospital Center, New York, NY
Demetria Cain, MPH , Center for HIV/AIDS Educational Studies and Training (CHEST), Hunter College of the City University of New York (CUNY), New York, NY
Sitaji Gurung, MD, MPH , Center for HIV/AIDS Educational Studies and Training (CHEST), Hunter College of the City University of New York (CUNY), New York, NY
Background: Substance use among HIV-positive persons exacerbates health problems. This study sought to estimate the prevalence of alcohol and drug-use problems among HIV-positive patients in NYC.

Methods: This retrospective cohort study includes electronic medical records (EMRs) of 5,584 HIV-positive patients who attended comprehensive care clinics in NYC in 2012.  EMRs were used to obtain estimates of the prevalence of alcohol and drug-use problems based on ICD-9/10 diagnoses of abuse/dependence.

Results: In the prior year, 11% of patients had an alcohol-use problem (no racial/ethnic differences were found). More Black patients (33.6%) had a drug-use problem, followed by Latino (30.7%) and White (30.0%) patients, with fewer “other” race patients having a problem (23.6%, p<.01). Gender comparisons revealed that a smaller proportion (2.7%) of transgender patients (74) had an alcohol-use problem than both cisgender males (11.6%) and females (11.0%, p=.05); females (37.0%) had significantly higher rates of drug problems than males (30.2%) and transgender patients (27.0%, p<.001). A significantly smaller proportion of MSM (10.5%) had an alcohol or drug-related problem (10.5% and 26.6%, respectively) than non-MSM (12.4% and 37.8%, respectively, p < .01). Three-quarters of patients with an alcohol problem also had a co-morbid drug problem and compared with patients with no alcohol problem, had nearly 9 times the odds of having a drug problem. 

Conclusions: Contrary to previous studies showing higher rates of substance use among HIV-positive MSM and transgender populations, our results found these groups had lower rates.  Further examination of the extent of such comorbidity is instrumental for intervention efforts.

Learning Areas:

Public health or related research
Social and behavioral sciences

Learning Objectives:
Describe alcohol and drug-use problems among HIV-positive patients in NYC Examine sociodemographic differences in alcohol and drug-use problems among HIV-positive patients in NYC Discuss implications for behavioral interventions to improve HIV-related health outcomes among HIV-positive individuals

Keyword(s): HIV/AIDS, Alcohol Use

Presenting author's disclosure statement:

Qualified on the content I am responsible for because: I have been conducting research on gay and bisexual men's sexual health for more than 20 years. I am a Distinguished Professor of Psychology at Hunter college and my accomplishments include more than 175 authored and co-authored manuscripts, serving on the editorial board of numerous journals in the field, and serving as the principal investigator on many large, NIH-funded research projects.
Any relevant financial relationships? No

I agree to comply with the American Public Health Association Conflict of Interest and Commercial Support Guidelines, and to disclose to the participants any off-label or experimental uses of a commercial product or service discussed in my presentation.

Back to: 5057.0: Substance Use and HIV/AIDS